Suchergebnisse - "9RV78Q2002"

PubPharm (1.001)

1

ENTERPRET : A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Jairath, V. | Yarur, A. | Osterman, M. | +6

2

Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease

enthalten in: Journal of pediatric gastroenterology and nutrition | 2024

von Rowland, P. | McNicol, M. | Kiel, A. | +5

3

Early Versus Late Use of Vedolizumab in Ulcerative Colitis : Clinical, Endoscopic, and Histological Outcomes

enthalten in: Journal of Crohn's & colitis | 2024

von Vermeire, S. | Hanzel, J. | Löwenberg, M. | +38

4

Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease

enthalten in: Transplantation and cellular therapy | 2024

von Chopra, Y. | Acevedo, K. | Muise, A. | +8

5

Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis

enthalten in: Expert review of clinical pharmacology | 2024

von D'Haens, G. | Rosario, M. | Polhamus, D. | +7

6

Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis

enthalten in: Inflammatory bowel diseases | 2024

von Adimadhyam, S. | Lewis, J. | Simon, A. | +13

7

Comparing the efficacy of vedolizumab between males and females : a post-hoc analysis of GEMINI-1 and VARSITY

enthalten in: European journal of gastroenterology & hepatology | 2024

von Chhibba, T. | Wong, E. | Reinisch, W. | +2

8

Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?

enthalten in: European journal of gastroenterology & hepatology | 2024

von Tepeš, K. | Hanžel, J. | Štubljar, D. | +31

9

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

enthalten in: BMC gastroenterology | 2024

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +14

10

Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease : impact on trough levels, day hospital visits, and medical expenses

enthalten in: Scandinavian journal of gastroenterology | 2024

von Harno-Tasihin, J. | Siregar, L. | Paajanen, M. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[101]